Personnel Moves Archives - Page 5 of 42

Zimmer Biomet adds longtime orthopedic hospital leader to its board

Zimmer Biomet (NYSE: ZBH) + announced today that it appointed Louis A. Shapiro to its board of directors, effective immediately.

Shapiro previously served as president and CEO of the Hospital for Special Surgery (HSS). HSS, an academic center focused on musculoskeletal health, held the No. 1 ranking in U.S. orthopedic hospitals for 14 years in a row, as selected by U.S. News & World Report. It held the No. 1 spot in worldwide orthopedic hospitals ranked by Newsweek for the past four consecutive years.

He spent 17 years at HSS, joining as president and CEO in October 2006 before retiring in October 2023. Before joining HSS, Shapiro worked at Geisinger Health System from 2002 to 2006. There, he held a number of positions, ultimately serving as EVP and COO of the Clinical Enterprise.

Additionally, Shapiro served as a senior healthcare expert and consultant at McKinsey & Co. from 1999-2002. He held a number …

Stanford Biodesign co-founder joins Sofinnova Partners

Dr. Josh Makower [Image from his LinkedIn page]Sofinnova Partners — a prominent life sciences venture capital firm based in Paris, London, and Milan — has added Stanford Biodesign co-founder and director Dr. Joshua Makower as an advisory venture partner.

It’s been 23 years since Makower co-founded Stanford Biodesign alongside Dr. Paul Yock. They were instrumental in devising “The Biodesign Process” — used to teach students and industry leaders at Stanford and worldwide.

Makower is also the founder and executive chair of medical device incubator ExploraMed, which has launched 11 companies since 1995. His work has led to significant developments in the field — including the creation of NeoTract, maker of a device and procedure to treat an enlarged prostate; Acclarent, creator of devices for minimally invasive sinus surgeries; and TransVascular, which pioneered transvascular procedures. Teleflex, Johnson & Johnson, and Medtronic acquired the com…

Covalon Technologies names longtime 3M, BD exec as CEO

Covalon Technologies (TSXV:COV) announced today that it appointed Brent Ashton as its new CEO and as a board director.

Ashton’s appointment goes into effect immediately. The medtech industry veteran has experience leading large business units for wound care, vascular access, infection prevention and diagnostics. His track record includes time spent at large medtech companies like 3M and BD.

Covalon develops technologies and solutions for advanced wound care, infection prevention, and medical device coatings. The company believes that, with his broad experience, Ashton can lead the company into its next phase of growth and development.

Board Chair Amir Boloor has served as interim CEO since September when former CEO Brian Pedlar departed the corner office.

“On behalf of the board, I am delighted to welcome Mr. Brent Ashton to Covalon as its new CEO,” Boloor said. “Brent’s extensive medtech industry expertise specifically as it rel…

AtriCure adds J&J veteran to its board

New AtriCure board member Shlomi Nachman. [Image from J&J]AtriCure (Nasdaq:ATRC) announced today that it appointed longtime Johnson & Johnson executive Shlomi Nachman to its board of directors.

Nachman most recently served as company group chair within the Johnson & Johnson Medical Devices (now MedTech) business. He also joined the board of transcatheter aortic valve replacement technology developer JenaValve in September.

“I am thrilled that Shlomi has joined the board of directors,” said Michael Carrel, president and CEO of AtriCure. “He is one of the most well-respected leaders in the medical device space, having led Johnson & Johnson’s medical device business through a period of unprecedented growth. His experience in the AFib market will be invaluable as we continue our mission of healing the lives of those affected by this global epidemic.”

More about new AtriCure board member Shlomi Nachman

With more than 25 years in the medical devic…

BiVacor picks former BioVentrix CEO for its corner office

New CEO Jim Dillon. [Image courtesy of BiVacor]Artificial heart maker BiVacor announced today that it appointed Jim Dillon as its new CEO and as a member of its board.

Dillon, an experienced medical device executive, most recently served as CEO of BioVentrix, a heart failure treatment developer. His appointment follows last week’s naming of Axonics CEO Raymond W. Cohen as board chair at BiVacor.

“Jim’s leadership style, combined with his experience in building high-performance teams as well as expertise in the heart failure field, makes him the ideal person to lead BiVACOR,” Cohen said in a news release. “We are thrilled to have him join as CEO.”

Dillon’s experience includes developing cardiovascular therapies to enable native heart recovery and reduce the size of myocardial infarction. It also extends to repairing adult and congenital cardiac defects and volume management for congestive heart failure patients.

Prior to his time at BioVen…

BCI developer Synchron names new chief technology officer

Synchron Chief Technology Officer Riki Banerjee [Photo courtesy of Synchron]Synchron has promoted Riki Banerjee to chief technology officer, replacing co-founder Nick Opie in the role.

Opie will remain on the brain-computer interface (BCI) developer’s board of directors, the company said today.

Banerjee joined Synchron as VP of R&D in September 2021 after 12 years with Medtronic’s neurovascular operating unit. She will now lead all of Synchron R&D activities, including advancing the company’s neuroprosthesis device for patients with severe paralysis.

“Riki has been an instrumental part of Synchron’s growth and has also been the driving force behind our product design,” Synchron CEO and co-founder Dr. Tom Oxley said in a news release. “She is a senior leader at the intersection of neuromodulation innovation, engineering, implantable medical devices and commercialization. Her expertise and leadership will be transfo…

Inspire Medical adds Intuitive CMO Dr. Myriam Curet to its board

Intuitive Surgical Chief Medical Officer Dr. Myriam Curet [Photo courtesy of Intuitive Surgical]Inspire Medical Systems (NYSE:INSP) announced today that it appointed Dr. Myriam J. Curet as an independent board director.

Curet’s appointment went into effect on Dec. 21, 2023. She currently serves as EVP and chief medical officer at surgical robotics pioneer Intuitive Surgical. Curet spoke to Medical Design & Outsourcing this year to explain the secret behind Intuitive’s surgical robotics success.

“We are excited to add Dr. Curet, a practicing, board-certified minimally invasive general surgeon with extensive business and executive leadership experience in the medical device industry to our board of directors,” said Tim Herbert, president and CEO of Inspire Medical Systems. “Dr. Curet brings significant experience in developing and commercializing scalable solutions for minimally invasive surgery and we look forward to her guidance, expertise and cont…

Artificial heart maker BiVacor names Axonics CEO as chair of its board

New BiVacor Chair Raymond W. Cohen. [Image from Axonics]BiVacor announced today that it appointed Axonics CEO Raymond W. Cohen as the new chair of its board of directors.

Cohen serves as CEO and as a member of the board at Axonics, which develops sacral neuromodulation technologies. He originally founded Axonics in 2013 and took the Irvine, California-based company public in October 2018. The long-time executive has more than 40 years of experience in the life sciences industry.

In addition to his roles at Axonics, Cohen serves as an independent director of SoniVie. The clinical-stage, venture-backed company develops denervation technology for uncontrolled hypertension.

Cohen now heads up the board at BiVacor, a company making a total artificial heart (BTAH). BiVacor received FDA investigational device exemption (IDE) for the artificial heart last month. It’s now set to conduct a first-in-human clinical feasibility study evaluating the use of the syst…

Bioventus names Medtronic, J&J veteran as CEO

Bioventus (Nasdaq:BVS) announced that it appointed Robert Claypoole as its new president and CEO, effective Jan. 10, 2024.

Claypoole succeeds Anthony Bihl, who served as interim CEO and board director since April 2023. Bihl took over in the interim role after Ken Reali stepped down for unknown reasons after three years in the corner office.

Durham, North Carolina-based Bioventus said in a news release that Claypoole brings more than 20 years of global commercial leadership experience in the medical device industry. He most recently served as EVP at Mölnlycke Health Care AB, leading its global wound care business.

Previously, Claypoole held senior positions at Medtronic, Covidien and Johnson & Johnson.

“We are excited to have Rob join Bioventus and build upon the significant improvements made this year to further elevate our execution and overall performance,” said William A. Hawkins, Bioventus’ executive chair. “Throughout his career, Rob has …

Merit Medical founder, CEO to retire in 2025

Fred Lampropoulos, Merit Medical founder, president and CEO.

Merit Medical Systems (Nasdaq:MMSI) announced that Fred Lampropoulos, its founder, CEO and president, intends to retire in two years.

The company outlined its ongoing CEO succession plan process with an amended and restated employment agreement. Lampropoulos intends to continue to serve as president and CEO through Dec. 31, 2025.

To carry out its CEO succession responsibilities, the Merit board appointed a special steering committee of independent directors. Ann Millner serves as lead independent director of the committee overseeing the plan in preparation for the CEO’s retirement.

According to a news release, Merit plans to prepare the company for a CEO transition “at the appropriate time.” It enlisted executive search firm Korn Ferry to assist the board in identifying potential internal and external candidates.

Merit said it doesn’t intend to provide further upd…

Former J&J MedTech head Ashley McEvoy takes board role at consumer goods giant

Ashley McEvoy [Image courtesy of Procter & Gamble]Less than two months after announcing her departure from Johnson & Johnson MedTech, Ashley McEvoy has taken on a role on the board of Procter & Gamble.

In October, the former EVP and worldwide chair at J&J MedTech announced her intention to leave the world’s second-largest medical device manufacturer. Tim Schmid took over the position from McEvoy, who spent 27 years at J&J. The reason behind her departure was “to pursue new opportunities,” she said.

While the seasoned medtech executive has yet to share any planned C-level moves, she has a new position on the board at a major consumer goods company in Procter & Gamble. Her appointment to the company’s board of directors went into effect on Dec. 12.

Over the course of her time at J&J, McEvoy most recently led the MedTech unit and spearheaded efforts to develop integrated, digitized solutions. She brought the busine…

BCI maker Synchron adds former Dexcom CEO to its board

Andy Rasdal [Image courtesy of Synchron]Brain-computer interface (BCI) developer Synchron announced today that it appointed medtech veteran Andy Rasdal to its board of directors.

Rasdal brings more than 30 years of experience in developing and commercializing novel medical devices. He previously served as CEO of Dexcom, a leader in the continuous glucose monitor (CGM) space. There, he led the company through FDA approval and a successful IPO on the way to commercializing its CGM technology.

Currently, Rasdal serves as executive chair of Epitel, which develops a wearable, wireless EEG system to detect seizure conditions. He also led Obalon through FDA approval, an IPO and the commercialization of an obesity product as founding CEO.

Other previous roles include president of Medtronic’s Vascular unit. Rasadal also served as VP of global marketing at Arterial Vascular Engineering, which Medtronic bought for $4.3 billion. He also held positions at EP Techn…